

# United States Food and Drug Administration

Center for Drug Evaluation and Research

10903 New Hampshire Ave, Silver Spring, MD 20993, United States of America

CDERExportCertificateProgram@fda.hhs.gov - Telephone (301) 796-4950

## Certificate of a Pharmaceutical Product - Active Pharmaceutical Ingredient (API)

Certificate Number: **WPWN-62TV**


Certificate Issue Date: **September 22, 2017**

Certificate Expiration Date: **September 21, 2019**

Importing Country: **ITALY**

Exporting Country: **UNITED STATES of AMERICA**

|         |  |
|---------|--|
| 1.      | Drug Trade Name, International or National non-proprietary name (as applicable) & dosage form: <b>ZINC OXIDE</b>   |
| 1.1     | Active Ingredient(s) and amount(s) per unit dose (complete quantitative composition is preferred): <b>See Attachments</b>  |
| 1.2     | Is this product licensed to be placed on the market for use in the exporting country? <b>No</b>  |
| 1.3     | Is this product actually on the market in the exporting country? <b>Yes</b>  |
| 2.B.1   | Applicant for certificate name & address: <b>Zinc Oxide LLC, 600 Printwood Drive, Dickson, TN 37055 United States of America</b>   |
| 2.B.2   | Status of Applicant: <b>Manufacturer</b>   |
| 2.B.2.1 | Manufacturer name & address: <b>Zinc Oxide LLC, 600 Printwood Drive, Dickson, TN 37055 United States of America</b>  |
| 2.B.3   | Why is marketing authorization lacking? <b>Not Applicable</b>  |
| 2.B.4   | Remarks: <b>The firm proposes to export the active pharmaceutical ingredients (API) listed above, which when properly labeled with statement "Caution: For further manufacturing, processing or repacking", may be freely marketed in the United States of America at this time.</b> |
| 3.      | Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? <b>Yes</b>  |
| 3.1     | Periodicity of routine inspections (years): <b>Pursuant to section 510(h)(3) of the Federal Food, Drug &amp; Cosmetic Act, Inspections will occur in accordance with a risk-based schedule</b>   |
| 3.2     | Has the manufacture of this type of dosage form been inspected? <b>Yes</b>   |
| 3.3     | Do the facilities and operations conform to GMPs as recommended by the WHO? (GMPs including 21 Code of Federal Regulations parts 210, 211, or ICH Q7A): <b>Yes, at time of inspection, site complies with FDA cGMP</b>   |
| 3.4     | Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product undertaken by another party? <b>Yes</b>  |



Andrei Perlloni, Branch Chief  
Drug Import Export Compliance Branch  
Division of Imports, Exports & Recalls  
Office of Drug Security, Integrity & Response

